Literature DB >> 1974503

The use of carvedilol in elderly hypertensive patients.

T O Morgan1, A Anderson, J Cripps, W Adam.   

Abstract

Carvedilol, a beta-blocking drug with vasodilator activity, has been used in 4 studies in 107 elderly patients with essential hypertension and has reduced blood pressure effectively. In the first study the pharmacokinetics and clinical response were compared between 21 patients greater than 65 years of age and 8 patients aged 35-50 years). The peak blood levels, time to maximal concentration, area under the curve, half-life and trough level of the drug with chronic administration did not differ. The clinical responses to the drug were similar, with a greater fall in systolic blood pressure in the older group. However the initial systolic blood pressure in the older group was higher. Carvedilol was compared with metoprolol, pindolol and nitrendipine in elderly patients. The responses to carvedilol were at least equal to those obtained with the other drugs. Control was achieved in the three studies with once-daily therapy. There was no significant postural hypotensive effect. A feature of all studies was the large number of patients who responded to carvedilol. The side-effect profile of the drug was acceptable; headache and dizziness were more common than with placebo or the comparison drugs and were frequently associated. There were no adverse biochemical effects and the lipid profile was not altered. Carvedilol is an effective antihypertensive drug that lowers blood pressure equally well in the young and the old.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1974503     DOI: 10.1007/bf01409482

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Efficacy and safety of carvedilol in the treatment of hypertension.

Authors:  E Schnurr; L Widmann; M Glocke
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Pharmacokinetics and disposition of carvedilol in humans.

Authors:  G Neugebauer; W Akpan; E von Möllendorff; P Neubert; K Reiff
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.

Authors:  T Ogihara; M Ikeda; Y Goto; K Yoshinaga; Y Kumahara; O Iimura; M Ishii; E Murakami; T Takeda; T Kokubu
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

4.  Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension.

Authors:  R Eggertsen; R Sivertsson; L Andrén; L Hansson
Journal:  J Hypertens       Date:  1984-10       Impact factor: 4.844

5.  Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance.

Authors:  T Morgan; R Snowden; L Butcher
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

6.  A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.

Authors:  W J Louis; J J McNeil; B S Workman; O H Drummer; E L Conway
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 7.  A new molecule with vasodilating and beta-adrenoceptor blocking properties.

Authors:  U Abshagen
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

8.  Carvedilol for systemic hypertension.

Authors:  M E Heber; G S Brigden; M P Caruana; A Lahiri; E B Raftery
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

  8 in total
  7 in total

1.  Long-term hemodynamic effects of antihypertensive treatment.

Authors:  P Lund-Johansen; P Omvik; J E Nordrehaug
Journal:  Clin Investig       Date:  1992

2.  Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure.

Authors:  B K Krämer; K M Ress; C M Erley; T Risler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

4.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992

Review 5.  Clinical pharmacokinetics and pharmacodynamics of carvedilol.

Authors:  T Morgan
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

Review 7.  Carvedilol: a review of its use in chronic heart failure.

Authors:  Gillian M Keating; Blair Jarvis
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.